Literature DB >> 18821011

Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.

Laura Papi1, Anna Laura Putignano, Caterina Congregati, Ines Zanna, Francesco Sera, Doralba Morrone, Mario Falchetti, Marco Rosselli Del Turco, Laura Ottini, Domenico Palli, Maurizio Genuardi.   

Abstract

BACKGROUND: Germline mutations in the BRCA1 and BRCA2 tumour-suppressor genes predispose to early-onset breast and ovarian cancer. Although both genes display a highly heterogeneous mutation spectrum, a number of alterations recur in some populations. Only a limited number of founder mutations have been identified in the Italian population so far.
OBJECTIVE: To investigate the spectrum of BRCA1/BRCA2 mutations in a set of families originary from the Central-Eastern part of Tuscany and to ascertain the presence of founder effects. We also wanted to approximate the age of the most frequent BRCA1 founder mutation.
RESULTS: Overall, four distinct BRCA1 mutations accounted for a large fraction (72.7%) of BRCA1-attributable hereditary breast/ovarian cancer in families originary from this area. We identified common haplotypes for two newly recognised recurrent BRCA1 mutations, c.3228_3229delAG and c.3285delA. The c.3228_3229delAG mutation was estimated to have originated about 129 generations ago. Interestingly, male breast cancer cases were present in 3 out of 11 families with the c.3228_3229delAG mutation.
CONCLUSIONS: The observation that a high proportion of families with BRCA1 alterations from Central-Eastern Tuscany harbours a limited number of founder mutations can have significant impact on clinical management of at risk subjects from this area. In addition, the identification of a large set of families carrying an identical mutation that predisposes to breast and ovarian cancer provides unique opportunities to study the effect of other genetic and environmental factors on penetrance and disease phenotype.

Entities:  

Mesh:

Year:  2008        PMID: 18821011     DOI: 10.1007/s10549-008-0190-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  13 in total

1.  The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases.

Authors:  Ines Zanna; Piera Rizzolo; Francesco Sera; Mario Falchetti; Paolo Aretini; Giuseppe Giannini; Giovanna Masala; Alberto Gulino; Domenico Palli; Laura Ottini
Journal:  Eur J Hum Genet       Date:  2010-03-17       Impact factor: 4.246

Review 2.  HER2-positive male breast cancer: an update.

Authors:  Laura Ottini; Carlo Capalbo; Piera Rizzolo; Valentina Silvestri; Giuseppe Bronte; Sergio Rizzo; Antonio Russo
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-10-04

3.  Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant.

Authors:  Maria De Bonis; Angelo Minucci; Giovanni Luca Scaglione; Elisa De Paolis; Gianfranco Zannoni; Giovanni Scambia; Ettore Capoluongo
Journal:  Fam Cancer       Date:  2019-01       Impact factor: 2.375

Review 4.  A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Authors:  Fatemeh Karami; Parvin Mehdipour
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

5.  Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.

Authors:  Giulia Cini; Massimo Mezzavilla; Lara Della Puppa; Elisa Cupelli; Alessio Fornasin; Angela Valentina D'Elia; Riccardo Dolcetti; Giuseppe Damante; Sara Bertok; Gianmaria Miolo; Roberta Maestro; Paolo de Paoli; Antonio Amoroso; Alessandra Viel
Journal:  BMC Med Genet       Date:  2016-02-06       Impact factor: 2.103

6.  Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.

Authors:  Bella Pajares; Javier Porta; Jose María Porta; Cristina Fernández-de Sousa; Ignacio Moreno; Daniel Porta; Gema Durán; Tamara Vega; Inmaculada Ortiz; Carolina Muriel; Emilio Alba; Antonia Márquez
Journal:  BMC Cancer       Date:  2018-06-08       Impact factor: 4.430

7.  A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.

Authors:  Grazia Palomba; Angela Loi; Antonella Uras; Patrizia Fancello; Giovanna Piras; Attilio Gabbas; Antonio Cossu; Mario Budroni; Antonio Contu; Francesco Tanda; Antonio Farris; Sandra Orrù; Carlo Floris; Marina Pisano; Mario Lovicu; Maria Cristina Santona; Gennaro Landriscina; Laura Crisponi; Giuseppe Palmieri; Maria Monne
Journal:  BMC Cancer       Date:  2009-07-20       Impact factor: 4.430

8.  Inherited and acquired alterations in development of breast cancer.

Authors:  Piera Rizzolo; Valentina Silvestri; Mario Falchetti; Laura Ottini
Journal:  Appl Clin Genet       Date:  2011-11-14

9.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

10.  Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.

Authors:  Laura Caleca; Anna Laura Putignano; Mara Colombo; Caterina Congregati; Mohosin Sarkar; Thomas J Magliery; Carla B Ripamonti; Claudia Foglia; Bernard Peissel; Daniela Zaffaroni; Siranoush Manoukian; Carlo Tondini; Monica Barile; Valeria Pensotti; Loris Bernard; Laura Papi; Paolo Radice
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.